Imricor (ASX: IMR) Expands U.S. Market with FDA Pediatric Clearance for NorthStar System

Key Highlights

• FDA clears Imricor’s NorthStar® Mapping System and Vision-MR® Diagnostic Catheter for pediatric use in the United States.
• Approval expands the company’s addressable market to more than 250 U.S. children’s hospitals.
• Radiation-free MRI-guided cardiac procedures offer a new option for children requiring repeated catheterisations.
• Shares rose 13.57% to A$2.05, valuing Imricor at approximately A$725 million.

Australia’s medical technology sector continues to notch up regulatory milestones, with Imricor Medical Systems (ASX: IMR) receiving U.S. Food and Drug Administration (FDA) clearance to expand its MRI-guided cardiac technology to pediatric patients.

The approval covers both the company’s NorthStar® Mapping System and Vision-MR® Diagnostic Catheter, allowing Imricor to market the technology across patients of all ages in the United States. The latest clearance broadens the company’s commercial opportunity, particularly among specialist children’s hospitals where reducing radiation exposure is a growing clinical priority.

The announcement builds on Imricor’s recent regulatory momentum. Last month, the company submitted the third Premarket Approval (PMA) module for its broader electrophysiology platform. Earlier this year, it also secured FDA clearance for NorthStar in adult patients. 

(Read our previous coverage: Imricor Receives FDA Clearance for Vision-MR Catheter.)

Thursday’s announcement represents another step in the company’s strategy to commercialise MRI-guided cardiac procedures across the U.S. healthcare system.

Unlike conventional cardiac catheterisations that typically involve fluoroscopy, or X-ray imaging, Imricor’s technology enables procedures to be performed entirely inside an MRI suite. That removes procedure-related radiation exposure while allowing clinicians to visualise soft tissue in greater detail during interventions.

The potential clinical impact may be particularly significant for younger patients. Children born with congenital heart defects often undergo multiple cardiac catheterisation procedures throughout their lives, making cumulative radiation exposure an ongoing concern in pediatric cardiology.

According to the company, there are more than 250,000 diagnostic right and left heart catheterisations performed annually in the United States, creating a sizeable opportunity beyond its existing electrophysiology business. The pediatric clearance also gives Imricor access to more than 250 children’s hospitals across the country.

MRI-guided cardiac intervention remains an emerging area within cardiovascular medicine. While fluoroscopy continues to be the standard imaging method for most procedures, hospitals are increasingly exploring technologies that improve patient safety, reduce radiation exposure and streamline clinical workflows. Industry organisations, including the American Heart Association and the Society for Cardiovascular Magnetic Resonance, have highlighted the growing role of advanced cardiac imaging in improving procedural planning and patient care.

Imricor says it remains the first and only company offering an MR-native 3D interventional cardiac mapping and guidance system, giving it a differentiated position as hospitals gradually adopt MRI-guided procedures.

Chair and Chief Executive Officer Steve Wedan said the latest FDA clearance reflects the company’s commitment to making radiation-free procedures available to all patient groups.

“We care about children, and we don’t shy away from delivering our products to all patient segments who can benefit from radiation-free iMR procedures.”

He added that the pediatric milestone carries particular personal significance.

“Having experienced first-hand, the pediatric use of products I personally developed throughout my career, I can say there is something particularly rewarding about providing technology to help infants and young children.”

Mr Wedan said the company’s broader vision remains unchanged.

“Changing the world of interventional medicine for doctors and patients means changing it for all doctors and all patients.”

While FDA clearance removes an important regulatory hurdle, commercial adoption will likely depend on hospital investment, physician training and workflow integration. The company is also continuing to pursue additional regulatory approvals, including its Advantage-MR EP Recorder/Stimulator, which would further expand its MRI-guided electrophysiology platform.

No surprise here that the market welcomed the latest update. Imricor shares climbed 13.57% to A$2.05 on Thursday morning, giving the company a market capitalisation of approximately A$724.66 million. The stock has traded between A$1.145 and A$2.25 over the past 12 months and has delivered a 30.99% one-year return.

Source: MarketIndex 

For Imricor, the latest FDA clearance is less about immediate revenue and more about steadily expanding the commercial reach of its technology. As regulatory milestones continue to fall into place, the company’s focus now shifts toward increasing hospital adoption and building a broader market for MRI-guided, radiation-free cardiac procedures in one of the world’s largest healthcare markets.